Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease - Wikidata - awgldk - TriplyDB

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

http://www.wikidata.org/entity/Q33740176

about

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment Role of bone-anabolic agents in the treatment of breast cancer bone metastases Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement Smad-dependent mechanisms of inflammatory bone destruction Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Treatment of multiple myeloma bone disease: experimental and clinical data.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma Novel therapeutic targets in myeloma bone disease.Bone metastasis: mechanisms and therapeutic opportunities.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Sotatercept in patients with osteolytic lesions of multiple myeloma.Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.Activin B antagonizes RhoA signaling to stimulate mesenchymal morphology and invasiveness of clear cell renal cell carcinomas.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Bone anabolic agents for the treatment of multiple myeloma.Targeting bone as a therapy for myeloma.Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response.Cancer-targeted therapies and radiopharmaceuticals TGF-β regulates sclerostin expression via the ECR5 enhancer.Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth The genetic pleiotropy of musculoskeletal aging.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma Utilizing BMP-2 muteins for treatment of multiple myeloma Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases.Novel Bruton's tyrosine kinase inhibitors currently in development.Multiple myeloma in the marrow: pathogenesis and treatments.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages Cellular mechanisms of multiple myeloma bone disease Bone and skeletal muscle: neighbors with close ties Mechanisms of multiple myeloma bone disease.Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.Contributions of the host microenvironment to cancer-induced bone disease.Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

P2860

Q24297354-C6D99300-7A92-4BF1-8DC9-9EEE11C5DEF5 Q26765477-31A9767D-8527-4468-8019-172B9DDB5B43 Q26822732-03D7D83D-36D8-42BC-90FE-9D3DC253900C Q27011865-3ECCE543-27E5-4445-9526-871FECCD9258 Q28066288-1646F3BA-2A07-4446-8BBC-DA2E51588D33 Q28082335-D92263CD-34A2-432F-B9FE-33F20ECD4FDB Q30868833-0AA18CDD-FD27-4EBD-AA70-4872AA1442F1 Q33856318-8F19B9BF-F328-4AEF-BBFD-3E3DD10DC63C Q34025065-8C113E96-8FBE-49E2-B89D-165319969C34 Q34025195-735FFEB0-9D37-4CC7-98C8-F6B1C0F71750 Q34038854-074FAFA6-044D-4921-8CD8-085B6F38AFC4 Q34292995-DB647FFF-2116-45E9-B99F-8FB613F46BCC Q34773850-1F640C92-34FE-4A9D-A4DE-29749F4BCDE9 Q35035011-147B69DE-BDC7-41F3-8DE4-58C786B9EF56 Q35097641-432E69FA-BBD0-4CD4-81DD-9BFA1392FB8C Q35364326-B6ED59E1-D067-4DB4-BB24-E9516C9363B7 Q35584866-4D50B517-1150-491B-AD4D-CEA6E82A95C7 Q35603116-D6E7AEA9-AF42-49C1-8FE3-56E5FEC8B8B9 Q35603128-13545B3B-F05E-421E-B8FA-CB40840062F9 Q35639228-718EAEB1-FB6D-454F-B4B3-83452086BF78 Q35683440-172B69F9-AE02-473C-BFBB-40EDBE49A01F Q35754103-C4D402FC-7E40-4C21-9B48-73DE000EF51D Q35943226-C7C019FC-894A-46E6-AE0D-BF528EA11A5F Q36086488-D898CF1F-A04B-43EB-AF86-D41DC3811E10 Q36092153-FD03F548-B5D8-4854-B3DC-FF8E90BE5D97 Q36193804-F7739D0F-70AE-4867-9840-9C0EC60260CF Q36206430-B3ECF925-AD95-4301-B55F-D2368D56E47C Q36367921-5DA98921-6535-4F07-91A3-A70DCD4570FE Q36402724-4D8837B4-E54E-4FAD-A1A3-0CE614289A51 Q36673755-0C3B2F78-0A1B-42C3-A5F3-7187CA7279F9 Q36725401-AF420B8B-8246-4FA3-8F4C-864CD7F57D21 Q36759374-216A82E5-416D-49B6-B821-DADD1ADBC66C Q36848283-3A3CD101-3987-4450-8951-BC2C159C51BF Q36896459-FCA85E5E-6201-4776-A7A5-DF1A9F4A6B4B Q36925346-7475C009-DA22-4688-8AEA-611AAEE94FDD Q36968228-4218AC11-9E1A-4534-AB8C-DB4B3269335B Q37056408-DA054306-ECF6-4E5D-893D-DF492E8C9928 Q37608433-EA6C2E90-D002-40AF-863D-93E28EACFE7C Q37663962-32508EDE-EC37-4F39-9CD7-F5D76E5D0936 Q37673351-1808E9B9-B27E-43CB-B1C4-D0FC1531B403

P2860

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

http://www.wikidata.org/entity/Q33740176

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Activin A promotes multiple my ...... arget for myeloma bone disease

@ast

Activin A promotes multiple my ...... arget for myeloma bone disease

@en

type

label

Activin A promotes multiple my ...... arget for myeloma bone disease

@ast

Activin A promotes multiple my ...... arget for myeloma bone disease

@en

prefLabel

Activin A promotes multiple my ...... arget for myeloma bone disease

@ast

Activin A promotes multiple my ...... arget for myeloma bone disease

@en

P1433

Q33740176-64B588D2-B5CE-4CA2-BCD8-2F313B3ED54C

P1476

Q33740176-7D041412-AB75-4F5F-AC38-27BB3CD1A6C9

P2093

Q33740176-0A42FA49-793B-44CD-BF2F-B36AC31A96DA

Q33740176-13CC145C-3149-49C6-90E3-5812572D6B58

Q33740176-1CC35256-8D8D-495F-BC8C-EC0650A69B21

Q33740176-24FD313D-2C11-459A-B5BC-7A3E4A15D396

Q33740176-28EFE2FF-BF73-42C8-9A3B-DD5C8FAF7B44

Q33740176-2BA550B1-42EA-4152-AF46-FAE3BE0E4303

Q33740176-2EEBDB8D-6B25-440D-B01B-A15153B196F8

Q33740176-373A2F3B-BB26-4CA6-8237-9643E9CF014A

Q33740176-3BBEBCE2-D60D-4667-9B9E-707380F3DD37

Q33740176-3D576264-79E8-4965-9C6A-91F860C820B6

P2860

Q33740176-016FA854-B8F7-4A01-B7A1-6572673143CA

Q33740176-111A1398-A6A6-4352-995C-3338C04EA44E

Q33740176-1518193C-5B4B-45E5-B633-8014636A7081

Q33740176-2630D5BC-B098-4E48-A259-EE0CD134EDFB

Q33740176-3C845267-8C10-400D-9982-0592ABEDC9AB

Q33740176-529B5AAD-414F-4FA6-8618-68E6AC2AA089

Q33740176-5EC090FD-A877-46EA-BF7D-5F7A678CC1A1

Q33740176-6B496483-30B6-408A-B292-451C24B0D47F

Q33740176-8513BB85-8D88-4F1A-9196-B88C62C05D7B

Q33740176-9C433978-D75A-44ED-B147-2A55EE81F3C1

P304

Q33740176-10EF0581-48E9-4588-9BC2-B2BE44BAD101

P31

Q33740176-B18A6452-6ABC-4F92-94B5-10D45E72B427

P356

Q33740176-580720C2-0626-48FD-B0E3-155346ACA66D

P407

Q33740176-EC3DB4CB-8882-4CC7-8631-F2DD3EF198DD

P433

Q33740176-AF550C8B-A612-4672-B550-EDA6B0FDC9BF

P478

Q33740176-97454680-901C-4692-8BB8-86D4DEE0008D

P50

Q33740176-4A529F74-A63E-41EC-94DD-05393D74BAFB

Q33740176-94634F78-27E9-43C6-AAD8-0947285EB0EF

Q33740176-B0E5FCDF-7F75-40A3-8823-CAC65EB683F0

Q33740176-CBAFA6DC-4E3F-4D3E-8083-668297D55526

Q33740176-E854BD51-45A4-41D1-9C33-28AF01E604E7

P577

Q33740176-812EB472-D744-4503-9D20-5AA76540DBA2

P5875

Q33740176-F1FC04B5-19EC-4909-B90A-9423B5ECB2B7

P698

Q33740176-C38DA9A3-09AD-4B7D-8532-253767D1794C

P932

Q33740176-D2F28D6C-4ADC-40F6-AA6E-7B8F83D3D67C

P356

PNAS.0911929107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Activin A promotes multiple my ...... arget for myeloma bone disease

@en

P2093

Alex Guimaraes

http://www.w3.org/2001/XMLSchema#string

Aliyah R Sohani

http://www.w3.org/2001/XMLSchema#string

David T Scadden

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Diana Cirstea

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Eyal Attar

http://www.w3.org/2001/XMLSchema#string

Jasbir S Seehra

http://www.w3.org/2001/XMLSchema#string

Jesse A Schoonmaker

http://www.w3.org/2001/XMLSchema#string

Loredana Santo

http://www.w3.org/2001/XMLSchema#string

P2860

BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Human activin betaA gene. Identification of novel 5' exon, functional promoter, and enhancers

Regulation of osteoblastogenesis and bone mass by Wnt10b

BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression

TGF-beta signaling in tumor suppression and cancer progression

Cancer metastasis: building a framework

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

P304

5124-5129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0911929107

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41656829

http://www.w3.org/2001/XMLSchema#string

P698

20194748

http://www.w3.org/2001/XMLSchema#string

P932

2841922

http://www.w3.org/2001/XMLSchema#string